New Year’s is receding fast in the rearview mirror. And for many of us, our sincere resolutions about losing weight and ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

but not for long Eli Lilly is still slightly behind Novo Nordisk in terms of market share of the incretin class in obesity in the United States, but this is more a reflection of the inability of ...

The macroenvironment in 2025 looks grim as signs of a slowdown in the economy set in. The biotech industry experienced a choppy ride in 2024, and the same is likely in store in 2025. Given the ...

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

World stocks are mixed follow Wall Street’s mostly positive performance ahead of key U.S. inflation data that could influence ...

Is your New Year’s resolution to cut back on alcohol? Dry January is here and Brevard County has plenty of mocktail options.

In fact, in the United States, an estimated 50% of children and ... “Genetic factors and obesity may cause unhealthy cholesterol levels in children,” says Jerome L. Fleg, MD, FACC, FAHA ...

“These findings suggest that BMI and obesity prevalence in the U.S. decreased in 2023 for the first time in more than a decade,” the authors write. “The most notable decrease was in the South, which ...

A group of global experts is proposing a new way to define and diagnose obesity, reducing the emphasis on the controversial body mass index and hoping to better identify people who need treatment ...